Pelvic Inflammatory Disease: Diagnosis, Management, and Prevention
Am Fam Physician. 2019 Sep 15;100(6):357-364.
Patient information: See related handout on pelvic inflammatory disease.
Author disclosure: No relevant financial affiliations.
Pelvic inflammatory disease (PID) is an infection of the upper genital tract occurring predominantly in sexually active young women. Chlamydia trachomatis and Neisseria gonorrhoeae are common causes; however, other cervical, enteric, bacterial vaginosis–associated, and respiratory pathogens, including Mycobacterium tuberculosis, may be involved. PID can be acute, chronic, or subclinical and is often underdiagnosed. Untreated PID can lead to chronic pelvic pain, infertility, ectopic pregnancy, and intra-abdominal infections. The diagnosis is made primarily on clinical suspicion, and empiric treatment is recommended in sexually active young women or women at risk for sexually transmitted infections who have unexplained lower abdominal or pelvic pain and cervical motion, uterine, or adnexal tenderness on examination. Mild to moderate disease can be treated in an outpatient setting with a single intramuscular injection of a recommended cephalosporin followed by oral doxycycline for 14 days. Additionally, metronidazole is recommended for 14 days in the setting of bacterial vaginosis, trichomoniasis, or recent uterine instrumentation. Hospitalization for parenteral antibiotics is recommended in patients who are pregnant or severely ill, in whom outpatient treatment has failed, those with tubo-ovarian abscess, or if surgical emergencies cannot be excluded. Treatment does not change in patients with intrauterine devices or those with HIV. Sex partner treatment is recommended; expedited partner treatment is recommended where legal. Prevention of PID includes screening for C. trachomatis and N. gonorrhoeae in all women younger than 25 years and those who are at risk or pregnant, plus intensive behavioral counseling for all adolescents and adults at increased risk of sexually transmitted infections.
Pelvic inflammatory disease (PID) includes an array of infectious processes that damage the endometrium, fallopian tubes, ovaries, and pelvic peritoneum. Sexually transmitted infections (STIs) cause most PID cases, but organisms associated with bacterial vaginosis (BV) have also been implicated. Approximately 15% of untreated chlamydial infections progress to PID; this percentage may be higher with gonococcal infections.1 Delayed diagnosis contributes to inflammatory sequelae, including infertility, ectopic pregnancy, and chronic pelvic pain.2,3 Approximately one in six women with salpingitis develops infertility.2,3 The cost of having PID has previously been estimated at $1,995 per patient, not including expenses for future evaluation and treatment of complications.4 Based on the National Health and Nutrition Examination Survey 2013–2014 data, 4.4% of women (2.5 million) 18 to 44 years of age in the United States reported a history of PID.5 Although studies suggest an overall decline in rates of PID, cases of gonorrhea and chlamydia are increasing.6 This is especially worrisome with the rise of antibiotic-resistant Neisseria gonorrhoeae.
WHAT IS NEW ON THIS TOPIC:
Because of emerging resistance, routine use of quinolones is no longer recommended for pelvic inflammatory disease to provide empiric coverage for gonorrhea.
Intrauterine devices pose no increased risk of pelvic inflammatory disease beyond the first 20 days postinsertion.
Intrauterine devices do not need to be removed if the patient with pelvic inflammatory disease is clinically improving within 48 to 72 hours of initiation of antibiotics.
SORT: KEY RECOMMENDATIONS FOR PRACTICE
|Clinical recommendation||Evidence rating||Comments|
Consensus guideline from the Centers for Disease Control and Prevention
Multicenter RCT showing no differences in reproductive outcomes between inpatient and outpatient treatment in mild to moderate PID
Consensus guideline and RCT of expedited therapy showing reduction in rates of STI
Consensus guideline and U.S. Preventive Services Task Force guideline with B recommendation
PID = pelvic inflammatory disease; RCT = randomized controlled trial; STI = sexually transmitted infection.
A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual pr
Referencesshow all references
1. Price MJ, Ades AE, De Angelis D, et al. Risk of pelvic inflammatory disease following Chlamydia trachomatis infection: analysis of prospective studies with a multistate model. Am J Epidemiol. 2013;178(3):484–492....
2. Haggerty CL, Gottlieb SL, Taylor BD, et al. Risk of sequelae after Chlamydia trachomatis genital infection in women. J Infect Dis. 2010; 201(suppl 2):S134–S155.
3. Ness RB, Soper DE, Holley RL, et al. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trial. Am J Obstet Gynecol. 2002;186(5):929–937.
4. Chesson HW, Collins D, Koski K. Formulas for estimating the costs averted by sexually transmitted infection (STI) prevention programs in the United States. Cost Eff Resour Alloc. 2008;6:10.
5. Kreisel K, Torrone E, Bernstein K, et al. Prevalence of pelvic inflammatory disease in sexually experienced women of reproductive age — United States, 2013–2014. MMWR Morb Mortal Wkly Rep. 2017;66(3):80–83.
6. Centers for Disease Control and Prevention. Sexually transmitted disease surveillance 2017. Accessed May 13, 2019. https://www.cdc.gov/std/stats17/default.htm
7. Simms I, Stephenson JM, Mallinson H, et al. Risk factors associated with pelvic inflammatory disease. Sex Transm Infect. 2006;82(6):452–457.
8. Workowski KA, Bolan GA; Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015 [published correction appears in MMWR Recomm Rep. 2015;64(33):924]. MMWR Recomm Rep. 2015;64(RR-03):1–137.
9. Haggerty CL, Totten PA, Tang G, et al. Identification of novel microbes associated with pelvic inflammatory disease and infertility. Sex Transm Infect. 2016;92(6):441–446.
10. Ness RB, Hillier SL, Kip KE, et al. Bacterial vaginosis and risk of pelvic inflammatory disease. Obstet Gynecol. 2004;104(4):761–769.
11. Brunham RC, Gottlieb SL, Paavonen J. Pelvic inflammatory disease. N Engl J Med. 2015;372(21):2039–2048.
12. Patton DL, Moore DE, Spadoni LR, et al. A comparison of the fallopian tube's response to overt and silent salpingitis. Obstet Gynecol. 1989;73(4):622–630.
13. Gaitán H, Angel E, Diaz R, et al. Accuracy of five different diagnostic techniques in mild-to-moderate pelvic inflammatory disease. Infect Dis Obstet Gynecol. 2002;10(4):171–180.
14. Yudin MH, Hillier SL, Wiesenfeld HC, et al. Vaginal polymorphonuclear leukocytes and bacterial vaginosis as markers for histologic endometritis among women without symptoms of pelvic inflammatory disease. Am J Obstet Gynecol. 2003;188(2):318–323.
15. Soper DE. Pelvic inflammatory disease. Obstet Gynecol. 2010;116(2 pt 1):419–428.
16. Parasar P, Ozcan P, Terry KL. Endometriosis: epidemiology, diagnosis and clinical management. Curr Obstet Gynecol Rep. 2017;6(1):34–41.
17. Kitaya K, Takeuchi T, Mizuta S, et al. Endometritis: new time, new concepts. Fertil Steril. 2018;110(3):344–350.
18. Frassetto L, Kohlstadt I. Treatment and prevention of kidney stones: an update. Am Fam Physician. 2011;84(11):1234–1242. Accessed July 19, 2019. https://www.aafp.org/afp/2011/1201/p1234.html
19. Lunny C, Taylor D, Hoang L, et al. Self-collected versus clinician-collected sampling for chlamydia and gonorrhea screening: a systemic review and meta-analysis. PLoS One. 2015;10(7):e0132776.
20. Van Dyck E, Ieven M, Pattyn S, et al. Detection of Chlamydia trachomatis and Neisseria gonorrhoeae by enzyme immunoassay, culture, and three nucleic acid amplification tests. J Clin Microbiol. 2001;39(5):1751–1756.
21. Sakhel K, Benson CB, Platt LD, et al. Begin with the basics: role of 3-dimensional sonography as a first-line imaging technique in the cost-effective evaluation of gynecologic pelvic disease. J Ultrasound Med. 2013;32(3):381–388.
22. Molander P, Sjöberg J, Paavonen J, et al. Transvaginal power Doppler findings in laparoscopically proven acute pelvic inflammatory disease. Ultrasound Obstet Gynecol. 2001;17(3):233–238.
23. Revzin MV, Mathur M, Dave HB, et al. Pelvic inflammatory disease: multimodality imaging approach with clinical-pathologic correlation. Radiographics. 2016;36(5):1579–1596.
24. Wiesenfeld HC, Hillier SL, Meyn LA, et al. Subclinical pelvic inflammatory disease and infertility. Obstet Gynecol. 2012;120(1):37–43.
25. Hillis SD, Joesoef R, Marchbanks PA, et al. Delayed care of pelvic inflammatory disease as a risk factor for impaired fertility. Am J Obstet Gynecol. 1993;168(5):1503–1509.
26. Ness RB, Trautmann G, Richter HE, et al. Effectiveness of treatment strategies of some women with pelvic inflammatory disease [published correction appears in Obstet Gynecol. 2006;107(6):1423–1425]. Obstet Gynecol. 2005;106(3):573–580.
27. Campagna JD, Bond MC, Schabelman E, et al. The use of cephalosporins in penicillin-allergic patients. J Emerg Med. 2012;42(5):612–620.
28. Grimes DA. Intrauterine device and upper-genital-tract infection. Lancet. 2000;356(9234):1013–1019.
29. Tepper NK, Steenland MW, Gaffield ME, et al. Retention of intrauterine devices in women who acquire pelvic inflammatory disease: a systematic review. Contraception. 2013;87(5):655–660.
30. Irwin KL, Moorman AC, O'Sullivan MJ, et al. Influence of human immunodeficiency virus infection on pelvic inflammatory disease. Obstet Gynecol. 2000;95(4):525–534.
31. Hosenfeld CB, Workowski KA, Berman S, et al. Repeat infection with chlamydia and gonorrhea among females: a systematic review of the literature. Sex Transm Dis. 2009;36(8):478–489.
32. Golden MR, Whittington WL, Handsfield HH, et al. Effect of expedited treatment of sex partners on recurrent or persistent gonorrhea or chlamydial infection. N Engl J Med. 2005;352(7):676–685.
33. Herzog SA, Heijne JC, Scott P, et al. Direct and indirect effects of screening for Chlamydia trachomatis on the prevention of pelvic inflammatory disease. Epidemiology. 2013;24(6):854–862.
34. LeFevre ML. Screening for chlamydia and gonorrhea: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;161(12):902–910.
35. American Academy of Family Physicians. Reproductive health clinical recommendations and guidelines. Accessed March 15, 2019. https://www.aafp.org/patient-care/browse/topics.tag-reproductive-health.html
36. ACOG practice bulletin no. 195: prevention of infection after gynecologic procedures. Obstet Gynecol. 2018;131(6):e172–e189.
37. Gradison M. Pelvic inflammatory disease. Am Fam Physician. 2012;85(8):791–796. Accessed July 19, 2019. https://www.aafp.org/afp/2012/0415/p791.html
38. Crossman SH. The challenge of pelvic inflammatory disease [published correction appears in Am Fam Physician. 2006;74(12):2024]. Am Fam Physician. 2006;73(5):859–864. Accessed July 29, 2019. https://www.aafp.org/afp/2006/0301/p859.html
39. Ross J, Cole M, Evans C, et al. United Kingdom National Guideline for the management of pelvic inflammatory disease (2019 interim update). Accessed July 17, 2019. https://www.bashhguidelines.org/media/1217/pid-update-2019.pdf
Copyright © 2019 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact firstname.lastname@example.org for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions